Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

ANAB

AnaptysBio Inc

Nov 26 • 04:00PM ET

42.16

+0.66 1.59 %

Healthcare • Biotechnology • USA • NASD

Nov 26, 4:06 PMAnaptysBio files a lawsuit against Tesaro and GSK alleging breach of the dostarlimab collaboration agreement, per SEC filing today.

Peers: REGN VRTX BMRN ALNY IONS SRPT EXEL BLUE INCY RGEN

| Held by: VTI IWM XBI IBB VXF IWO SCHA VTWO FFTY IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.82	Insider Own	5.95%	Shs Outstand	27.58M	Perf Week	13.92%
Market Cap	1.17B	Forward P/E	-	EPS next Y	-3.71	Insider Trans	-2.68%	Shs Float	26.04M	Perf Month	16.59%
Enterprise Value	1.26B	PEG	-	EPS next Q	0.86	Inst Own	112.63%	Short Float	22.77%	Perf Quarter	109.44%
Income	-84.63M	P/S	6.89	EPS this Y	71.54%	Inst Trans	-18.39%	Short Ratio	9.79	Perf Half Y	86.88%
Sales	169.47M	P/B	-	EPS next Y	-154.63%	ROA	-19.99%	Short Interest	5.93M	Perf YTD	218.43%
Book/sh	-1.07	P/C	4.69	EPS next 5Y	2.71%	ROE	-308.02%	52W High	43.31 -2.66%	Perf Year	89.31%
Cash/sh	8.99	P/FCF	-	EPS past 3/5Y	-34.42% -7.30%	ROIC	-26.87%	52W Low	12.21 245.29%	Perf 3Y	55.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	13.05% 62.73%	Gross Margin	98.57%	Volatility	9.66% 8.19%	Perf 5Y	60.55%
Dividend TTM	-	EV/Sales	7.46	EPS Y/Y TTM	53.92%	Oper. Margin	-16.92%	ATR (14)	2.77	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.68	Sales Y/Y TTM	196.42%	Profit Margin	-49.94%	RSI (14)	71.12	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	8.68	EPS Q/Q	145.80%	SMA20	14.40%	Beta	0.28	Target Price	63.91
Payout	-	Debt/Eq	-	Sales Q/Q	154.26%	SMA50	28.50%	Rel Volume	0.95	Prev Close	41.50
Employees	136	LT Debt/Eq	-	Earnings	Nov 04 AMC	SMA200	76.42%	Avg Volume	605.56K	Price	42.16
IPO	Jan 26, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	142.83% 248.19%	Trades		Volume	575,295	Change	1.59%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-13-25	Initiated	Barclays	Overweight	$78
Jun-04-25	Upgrade	H.C. Wainwright	Neutral → Buy	$38
Feb-04-25	Initiated	Wolfe Research	Outperform	$25
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral	$52 → $19
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy	$55
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight	$29 → $69
Apr-16-24	Initiated	Leerink Partners	Outperform	$47
Apr-11-24	Initiated	Wells Fargo	Overweight	$56
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform	$20 → $34
Feb-26-24	Initiated	BTIG Research	Buy	$55
Feb-21-24	Initiated	Stifel	Buy	$50
Feb-16-24	Initiated	Piper Sandler	Overweight	$80
May-22-23	Upgrade	JP Morgan	Underweight → Neutral	$31 → $30
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy	$44
Sep-19-22	Resumed	H.C. Wainwright	Buy	$35
Sep-13-22	Downgrade	Truist	Buy → Hold	$50 → $28
Sep-01-22	Initiated	Raymond James	Outperform	$35

Show Previous Ratings

Nov-25-25 04:15PM	Anaptys Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-21-25 04:47PM	AnaptysBio Reverses Higher After Trading Legal Barbs With Pharma Giant GSK (Investor's Business Daily) +5.18% +5.91%
06:14AM	GSK, AnaptysBio Sue Each Other Over Cancer Drug License (The Wall Street Journal)
04:00AM	Anaptys Announces $100 Million Stock Repurchase Plan (GlobeNewswire)
03:50AM	Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary (GlobeNewswire)
05:20AM	Loading…
Nov-12-25 05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-10-25 11:25AM	Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run (Investor's Business Daily) -14.30%
09:00AM	Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis (GlobeNewswire)
Nov-04-25 05:50PM	AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-29-25 10:00AM	Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:15AM	Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation (GlobeNewswire)
Oct-28-25 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-13-25 09:15AM	Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 (GlobeNewswire)
04:05PM	Loading…
Sep-29-25 04:05PM	Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 (GlobeNewswire) +31.59%
04:05PM	Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 (GlobeNewswire)
Aug-27-25 04:15PM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-06-25 05:25PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.63%
04:15PM	Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 10:00AM	AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jun-03-25 04:05PM	Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA (GlobeNewswire) +7.59% -9.57%
May-27-25 04:15PM	Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 (GlobeNewswire)
May-12-25 03:53PM	AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-05-25 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire) +7.82%
Mar-25-25 09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-24-25 09:15AM	Anaptys Announces Stock Repurchase Plan (GlobeNewswire) +9.54%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
06:55PM	Loading…
Feb-27-25 06:55PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Participation in March Investor Conferences (GlobeNewswire)
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-13-25 10:00AM	Truist says AnaptysBio handing of placebo raise doubt about Phase 2 RA data (TipRanks) +19.44%
09:40AM	Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? (Zacks)
05:11AM	AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? (Zacks)
Feb-12-25 12:22PM	AnaptysBio achieves highest ever results in Phase II rheumatoid arthritis trial (Clinical Trials Arena) +30.51%
09:23AM	AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment (Investor's Business Daily)
07:30AM	Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months (GlobeNewswire)
Feb-11-25 05:30PM	Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 (GlobeNewswire)
Feb-04-25 06:37AM	Vanda and AnaptysBio link for generalised pustular psoriasis therapy (Pharmaceutical Technology)
Feb-03-25 04:15PM	Anaptys to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire) -7.08%
07:30AM	Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist (PR Newswire)
Jan-27-25 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks)
Jan-13-25 09:42AM	How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry (Zacks)
Jan-12-25 03:00AM	Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser (Barrons.com)
Jan-07-25 09:15AM	Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 05:23AM	AnaptysBios atopic dermatitis trial of BTLA agonist misses endpoints (Clinical Trials Arena)
Dec-11-24 02:07PM	AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data (Benzinga) -32.83%
08:30AM	Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis (GlobeNewswire)
Nov-25-24 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks) +8.22%
Nov-08-24 12:00PM	AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) (Zacks)
Nov-05-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.72%
04:15PM	Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November and December Investor Conferences (GlobeNewswire)
Aug-29-24 09:15AM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-23-24 07:26AM	Why AnaptysBio Was Such a Healthy Stock This Week (Motley Fool)
Aug-14-24 04:11PM	AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily) -6.35%
10:05AM	AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily)
05:00AM	Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering (GlobeNewswire)
Aug-05-24 09:54PM	ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:55PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 10:00AM	AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-22-24 02:53PM	AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst (Benzinga) +5.96%
May-09-24 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.75%
04:15PM	Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
04:05PM	Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties (GlobeNewswire)
May-02-24 10:01AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-01-24 04:51AM	AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks) +6.90%
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-15-24 02:19PM	BTIG Research Predicts Over 118% Rally for These 3 Stocks (InvestorPlace) -6.34%
Apr-12-24 07:00PM	Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week (Motley Fool) -8.17%
Apr-09-24 02:40PM	Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock. (Zacks)
Mar-14-24 12:00PM	What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade (Zacks)
Mar-11-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.85% +11.61%
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 09:15AM	Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-19-24 05:54AM	Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength? (Zacks)
Jan-31-24 09:15AM	Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-12-24 03:02PM	AnaptysBio Inc CEO Daniel Faga Sells 6,866 Shares (GuruFocus.com)
Dec-07-23 09:55AM	Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire)
Nov-14-23 09:35AM	Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround (Zacks) +7.29%
Nov-07-23 04:15PM	Anaptys Named a BioSpace 2024 Best Places to Work Winner (GlobeNewswire) -6.17%
Nov-04-23 05:41AM	AnaptysBio Inc (ANAB) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
Nov-02-23 04:15PM	Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +8.21%
Nov-01-23 09:15AM	Anaptys Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-11-23 09:15AM	Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress (GlobeNewswire)
Oct-09-23 08:27AM	UPDATE 1-AnaptysBio's skin disease drug meets main goal in late-stage study (Reuters)
08:15AM	Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25 (GlobeNewswire)
08:05AM	AnaptysBio's skin disease drug meets main goal in late-stage study (Reuters)
08:00AM	Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
Sep-19-23 03:01PM	Insider Sell: Eric Loumeau Sells 6,000 Shares of AnaptysBio Inc (GuruFocus.com)
Sep-18-23 04:15PM	AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors (GlobeNewswire)

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 30 '25	Option Exercise	14.02	5,000	70,100	17,328	Oct 01 04:00 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 30 '25	Sale	29.00	8,240	238,960	9,088	Oct 01 04:00 PM
ERIC J LOUMEAU	Officer	Sep 30 '25	Proposed Sale	29.00	8,240	238,960		Sep 30 04:13 PM
Orwin John A	Director	Sep 15 '25	Option Exercise	0.00	1,300	0	10,665	Sep 17 04:02 PM
RENTON HOLLINGS	Director	Aug 08 '25	Option Exercise	6.93	10,231	70,901	15,196	Aug 12 04:02 PM
RENTON HOLLINGS	Director	Aug 08 '25	Sale	19.62	10,231	200,714	4,965	Aug 12 04:02 PM
HOLLINGS C RENTON	Director	Aug 08 '25	Proposed Sale	19.62	10,231	200,713		Aug 08 05:10 PM
RENTON HOLLINGS	Director	Jul 02 '25	Option Exercise	6.93	20,925	145,010	25,890	Jul 03 01:34 PM
RENTON HOLLINGS	Director	Jul 02 '25	Sale	23.57	20,925	493,191	4,965	Jul 03 01:34 PM
HOLLINGS C RENTON	Director	Jul 02 '25	Proposed Sale	23.57	20,925	493,190		Jul 02 04:13 PM
FENTON DENNIS M	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:07 PM
RENTON HOLLINGS	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:06 PM
HOLLINGS C RENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:26 PM
DENNIS M FENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:06 PM
Jain Rita	Director	Jun 15 '25	Option Exercise	0.00	7,330	0	11,864	Jun 17 06:33 PM
FENTON DENNIS M	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:33 PM
Marquet Magda	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,930	Jun 17 06:32 PM
Orwin John A	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,365	Jun 17 06:31 PM
RENTON HOLLINGS	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:30 PM
Schmid John P.	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	52,267	Jun 17 06:30 PM
Ware J. Anthony	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	13,530	Jun 17 06:29 PM
Schmid John P.	Director	Jan 13 '25	Option Exercise	6.50	42,337	275,007	46,237	Jan 15 05:04 PM
EcoR1 Capital, LLC	Director	Dec 30 '24	Buy	12.92	65,184	842,060	7,860,180	Jan 02 06:17 PM
EcoR1 Capital, LLC	Director	Dec 31 '24	Buy	12.93	13,268	171,513	7,873,448	Jan 02 06:17 PM
EcoR1 Capital, LLC	Director	Jan 02 '25	Buy	12.95	6,646	86,070	7,880,094	Jan 02 06:17 PM
RENTON HOLLINGS	Director	Nov 29 '24	Option Exercise	6.93	10,000	69,300	11,950	Dec 03 04:35 PM
RENTON HOLLINGS	Director	Nov 29 '24	Sale	25.00	10,000	250,000	1,950	Dec 03 04:35 PM
HOLLINGS C RENTON	Director	Nov 29 '24	Proposed Sale	25.00	10,000	250,000		Nov 29 01:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

ANAB

AnaptysBio Inc

Upgrade your FINVIZ experience